Follows patients with HER2-low breast cancer treated with trastuzumab deruxtecan
Observes adults with advanced HER2-low breast cancer receiving trastuzumab deruxtecan, a targeted drug.
Plain-language title generated from the registry record
Registry title: DESTINY Breast Respond HER2-(Ultra)Low Europe
Key facts
- Where
- Aalst, Auderghem, Bonheiden, Brasschaat, Bruges, Brussels, Haine-Saint-Paul, Hasselt, La Louvière, Liège, Namur, Ottignies, Sint-Niklaas, and Verviers, BelgiumSee the 16 sites
Where in Belgium
- ASZ AalstAalst, BelgiumNo longer taking part
- Chirec Delta HospitalAuderghem, BelgiumNo longer taking part
- Imeldaziekenhuis BonheidenBonheiden, BelgiumNo longer taking part
- AZ KLINABrasschaat, BelgiumNo longer taking part
- Az Sint-Jan Brugge AvBruges, BelgiumNo longer taking part
- CHU BrugmannBrussels, BelgiumNo longer taking part
- Cliniques universitaires Saint-LucBrussels, BelgiumNo longer taking part
- CHU HELORA - Hôpital de la Louvière - Site JolimontHaine-Saint-Paul, BelgiumNo longer taking part
- JESSA ZiekenhuisHasselt, BelgiumNo longer taking part
- CHU TivoliLa Louvière, BelgiumNo longer taking part
- CHC MontLégiaLiège, BelgiumNo longer taking part
- Hôpital de la CitadelleLiège, BelgiumNo longer taking part
- CHU UCL Namur / Site Sainte ElisabethNamur, BelgiumNo longer taking part
- Clinique Saint Pierre OttigniesOttignies, BelgiumNo longer taking part
- VitazSint-Niklaas, BelgiumNo longer taking part
- CHR Verviers East BelgiumVerviers, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Trial code
- NCT05945732
- Record updated
- 19 August 2026
- Original description
Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.Read full original descriptionShow less
A Prospective, Non-interventional Study (NIS) With Trastuzumab Deruxtecan For Patients With HER2-(Ultra)Low Expressing Unresectable and/or Metastatic Breast Cancer Accompanied By a Disease Registry of Patients Treated With Conventional Chemotherapy (DESTINY Breast Respond HER2-(Ultra)Low Europe)
Trastuzumab deruxtecan (T-DXd) as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
Based on the extended therapeutic indication of Trastuzumab deruxtecan (Enhertu®), a new patient population will be enrolled, comprising adult patients with unresectable or metastatic HR-positive, HER2-low, or HER2-(ultra)low breast cancer who have received at least one endocrine therapy in the metastatic setting and are not considered suitable for endocrine therapy as the next line of treatment.
Inclusion: Study Group 1 and Study Group 2; Adult patient (age ≥ 18 years) with histological or cytological confirmed diagnosis of unresectable and/or mBC; Decision to newly initiate therapy of T-DXd or conventional chemotherapy according to the physicians choice per SmPC; Written and signed Informed Consent to participate in the study; Study Group 1; Documented HER2-low status (IHC1+, IHC2+/ISH-); Patients who have received prior chemotherapy in the metastatic setting or; Patients who have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; Study Group 2:; Documented HR+ status; Documented HER2-low status (IHC1+ or IHC2+/ISH-) or HER2-ultralow (defined as IHC 0 with membrane staining [IHC > 0 to <1+]) status; Patients who have received at least one endocrine therapy in the metastatic setting; Patients who have NOT received prior chemotherapy in the metastatic setting.
Exclusion: Study Group 1 and Study Group 2; Pregnancy or breastfeeding; Patients who at time of data collection for this study are participating in or have participated in an interventional study that remains blinded; No other specific exclusion criteria are defined, as patients will be treated according to the proposed indication statements in the SmPC.